Martin and Harris Laboratories Limited Unlisted Share Price
As of , the indicative unlisted share price of Martin and Harris Laboratories Limited is ₹895 per share. This is an over-the-counter reference price, not a stock-exchange quote.
As of , Martin and Harris Laboratories Limited is not listed on any Indian stock exchange (NSE or BSE) — its shares trade in the unlisted, over-the-counter (pre-IPO) market.
| Price / unit | ₹895 |
|---|---|
| Market cap | ₹312 Cr |
| Min. investment | ₹13,425 |
| Lot size | 15 |
| P/E ratio | 4.71 |
| P/B ratio | 0.45 |
What is Martin and Harris Laboratories Limited?
Martin and Harris Laboratories Limited is an unlisted Pharmaceuticals company whose shares trade in India's over-the-counter (pre-IPO) market and settle in demat form (NSDL/CDSL).
Martin and Harris Laboratories Limited is an India-based pharmaceutical company incorporated in 1993 and headquartered in Gurgaon, Haryana. It is associated with the Apeejay Stya & Svran group and operates in the manufacturing of pharmaceuticals, medicinal chemicals and botanical products, with manufacturing units in Himachal Pradesh and Uttarakhand. Alongside its core pharmaceutical formulations business, the company maintains a treasury and investment portfolio that contributes a notable share of its income. It is a long-established manufacturer that has not listed on a public stock exchange. As an unlisted company, its equity shares are not traded on the NSE or BSE and change hands privately. Investors should note that unlisted and pre-IPO shares carry higher risk and lower liquidity than listed securities, may be difficult to value or exit, and prices can vary widely between counterparties. This information is provided for general reference only and is not investment advice.
Explore more unlisted shares
Other companies in our curated selection.
Frequently asked questions
No. As of 16 July 2026, Martin and Harris Laboratories Limited is an unlisted company whose shares trade over-the-counter; it would list only if and when it completes an IPO.
The minimum lot is 15 share(s); at the indicative price of about ₹895, that is approximately ₹13,425. Indicative reference, not a quote.
As of 16 July 2026, the indicative unlisted share price of Martin and Harris Laboratories Limited is ₹895 per share. This is an over-the-counter reference price, not a stock-exchange quote.
The ISIN of Martin and Harris Laboratories Limited is INE03VV01015. An ISIN is the unique 12-character code that identifies a company's shares in the depository system; this one is verified against NSDL (the National Numbering Agency). You need it to hold or transfer these unlisted shares in your NSDL or CDSL demat account.
Martin and Harris Laboratories Limited is an India-based pharmaceutical company incorporated in 1993 and based in Gurgaon, Haryana. It manufactures pharmaceuticals, medicinal chemicals and botanical products and is associated with the Apeejay Stya & Svran group, with manufacturing units in Himachal Pradesh and Uttarakhand. It also runs an investment and treasury portfolio that contributes a meaningful part of its income.
No. Martin and Harris Laboratories Limited is currently an unlisted company, meaning its shares are not traded on the NSE or BSE. Its equity is exchanged privately in the unlisted market. The company has the ISIN INE03VV01015 and CIN U24239HR1993PLC033630.
Unlisted shares are bought and sold through private off-market transactions and settled into your demat account. To learn about availability, indicative pricing and the transfer process, you can contact the Unlisted Axis team, who can walk you through the steps. This is general information and not a recommendation to buy or sell.
Unlisted and pre-IPO shares carry higher risk and lower liquidity than listed securities. There is no guarantee a company will list on an exchange, exiting a position can be difficult, prices can vary widely between buyers and sellers, and disclosures are typically less frequent than for listed firms. Consider your own risk tolerance and consult a qualified adviser before any decision.
They can. If the company declares a dividend, unlisted shareholders are eligible like any other shareholder. Many unlisted firms reinvest profits, so dividends are not guaranteed.
After listing, unlisted shares convert into regular listed shares in your demat account and can be traded on the exchange, usually once any applicable SEBI lock-in period ends.
Unlisted shares are less liquid than listed shares. You can sell when a buyer is available through an off-market transfer; there is no continuous exchange market, so exits can take longer.
Unlisted shares carry higher risk and lower liquidity than listed shares, with fewer disclosures and no live market price. This is general information, not investment advice — assess suitability before investing.
An unlisted share price is an indicative, over-the-counter reference set by demand and supply in private deals between buyers and sellers. There is no live exchange quote, so prices can vary across dealers and over time.
Yes. Unlisted shares are delivered in dematerialised form, so you need an active demat account (NSDL or CDSL). No special account type is required — a regular demat account works.
Unlisted shares are sold through an off-market transfer to a buyer via a registered intermediary, settling from your demat account with a contract note. Liquidity depends on buyer availability, so exits can take longer than listed shares.
Martin and Harris Laboratories Limited vs similar unlisted Pharmaceuticals shares
Indicative over-the-counter prices, as of 16 July 2026. Information only — not a recommendation or ranking.